Malignant Splenic Neoplasm — Trials

Malignant Splenic Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

170 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 21
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 10%
Top sponsor: City of Hope Medical Center
Termination share: 35.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (38)

clinicaltrialsPublishedShowing 1–12 of 12 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	terminated	Phase 2	20	University of NebraskaOTHER	1	Sep 6, 2023	clinicaltrials
NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	terminated	Phase 1 / Phase 2	20	Northwestern UniversityOTHER	1	Sep 1, 2021	clinicaltrials